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Speckle-tracking echocardiography 
combined with imaging mass 
spectrometry assesses region-
dependent alterations
Kathleen pappritz1,2,7, Jana Grune2,3,4,7, Oliver Klein1,2, Niklas Hegemann2,3, Fengquan Dong1, 
Muhammad el-Shafeey1,5, Jie Lin1, Wolfgang M. Kuebler2,3, Ulrich Kintscher2,4, 
carsten tschöpe1,2,6 & Sophie Van Linthout1,2,6*
Left ventricular (LV) contraction is characterized by shortening and thickening of longitudinal 
and circumferential fibres. To date, it is poorly understood how LV deformation is altered in 
the pathogenesis of streptozotocin (STZ)-induced type 1 diabetes mellitus-associated diabetic 
cardiomyopathy and how this is associated with changes in cardiac structural composition. To gain 
further insights in these LV alterations, eight-week-old C57BL6/j mice were intraperitoneally injected 
with 50 mg/kg body weight STZ during 5 consecutive days. Six, 9, and 12 weeks (w) post injections, 
echocardiographic analysis was performed using a Vevo 3100 device coupled to a 30-MHz linear-
frequency transducer. Speckle-tracking echocardiography (STE) demonstrated impaired global 
longitudinal peak strain (GLS) in STZ versus control mice at all time points. 9w STZ animals displayed an 
impaired global circumferential peak strain (GCS) versus 6w and 12w STZ mice. They further exhibited 
decreased myocardial deformation behaviour of the anterior and posterior base versus controls, which 
was paralleled with an elevated collagen I/III protein ratio. Additionally, hypothesis-free proteome 
analysis by imaging mass spectrometry (IMS) identified regional- and time-dependent changes of 
proteins affecting sarcomere mechanics between STZ and control mice. In conclusion, STZ-induced 
diabetic cardiomyopathy changes global cardiac deformation associated with alterations in cardiac 
sarcomere proteins.
Diabetic cardiomyopathy is an own clinical entity, which occurs in the absence of hypertension and coronary 
artery disease1,2. Experimental STZ-induced type 1 diabetes mellitus-associated diabetic cardiomyopathy is 
associated with enhanced cardiac cytokine levels and collagen I deposition, resulting in cardiac dysfunction3. 
Cumulative evidence shows that early diabetic cardiomyopathy manifests in LV diastolic dysfunction accom-
panied by low-grade inflammation lacking pronounced fibrosis4. Imaging techniques, like echocardiography5 
facilitate detection of alterations in diastolic performance.
In general, LV architecture is composed of longitudinal and circumferential fibres, building the endo-, meso-, 
and epicardial layers of the heart6. The orientation of the fibres within those layers is comprised of a right-handed 
helix in the subendocardium, circumferential oriented fibres in the cardiac midwall, and a left-handed helix in 
the subepicardium7. During cardiac contraction, fibres undergo shortening and thickening, whereby contraction 
of the subendocardial longitudinal fibres mainly determine LV function in longitudinal direction8. In contrast, 
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thickening of the mesocard contributes to circumferential and radial motion. Due to the opposite orientation of 
the subendocardial and subepicardial fibres, the shortening of these fibres determines cardiac twist during LV 
contraction. Recently, strain parameters assessed by STE, which reflect tissue deformation (strain) during the 
cardiac cycle, have been included in guideline recommendations for the diagnosis of heart failure9,10. In contrast 
to conventional echocardiography, STE is able to detect early subtle changes and has been shown to be of diag-
nostic value11,12. Studies in patients with heart failure with preserved ejection fraction13 and diabetes mellitus14 
demonstrated that GLS was initially impaired, but subsequently compensated by circumferential or radial func-
tion to maintain ejection fraction15. The authors hypothesized that diabetes-associated cardiac fibrosis particu-
larly occurs in the endo- and epicardial layers, which predominantly consist of longitudinal fibers. Therefore, 
enhanced fibrotic lesions in these layers will specifically cause a decline of longitudinal strain parameters16. To 
date, further evidence for this hypothesis is missing and the underlying mechanistic reason for impaired myocar-
dial deformation during diabetic cardiomyopathy remains poorly understood17.
Collagen is one of the most important proteins of the extracellular matrix and ensures myocardial structure 
and architecture18. After secretion as pro-peptides, collagen molecules are cleaved, followed by stabilization via 
cross-linking. Matrix metalloproteinases (MMPs) are responsible for collagen degradation, indicating their role 
as modulators in the maintenance of tissue homeostasis as well as in pathological remodelling. In heart failure, 
the equilibrium between MMPs and their tissue inhibitors (TIMPs) varies depending on the pathogenic entity19. 
Since several decades it is known that an enhanced collagen deposition in diabetic patients is associated with an 
impairment in LV function. We recently published data, which supports the hypothesis that a decline in GLS, 
indicative for reduced cardiac performance, strongly correlates with enhanced collagen and TIMP-1 levels20. 
Beside the relevance of cardiac fibrosis, there is accumulating evidence that particularly dysfunctionality of the 
contractile apparatus21, involving myosin and titin4,22, occurs at the early stage of diabetic cardiomyopathy.
Despite enormous progress in the understanding of the diabetes mellitus-associated changes in extracellular 
matrix turnover and expression of contractile proteins, there is still little known about their subsequent effects 
on cardiac deformation behaviour. To our knowledge, this is the first study investigating impaired global defor-
mation behaviour and associated alterations in the expression of cardiac structure components in experimental 
STZ-induced type 1 diabetes mellitus-associated diabetic cardiomyopathy.
Results
STZ-induced type 1 diabetes mellitus is associated with impaired morphological parameters. 
In accordance with previous studies23, mice suffering from type 1 diabetes mellitus displayed increases in blood 
glucose levels at 6w, 9w, and 12w after STZ application versus corresponding controls, respectively (Fig. 1a). In 
parallel, the body weight of STZ-treated mice was lower at 6w, 9w, and 12w compared to respective control mice 
(Fig. 1b). Additionally, we detected a decline in the LV mass of STZ mice at all three investigated time points ver-
sus the respective controls (Fig. 1c). LV mass/body weight ratios revealed a lower LV mass/body weight ratio only 
at 6w after STZ application versus the corresponding control mice (Fig. 1d). Surprisingly, 9w after type 1 diabetes 
mellitus induction, LV mass and LV mass/body weight were higher versus 6w and 12w STZ mice, respectively 
(Fig. 1c,d). To further resolve the question why 9w STZ differed from 6w and 12w STZ mice, subsequent experi-
ments and analysis were designed.
STZ-induced type 1 diabetes mellitus impairs diastolic and systolic function. As shown in Fig. 2, 
the mean diastolic LV anterior wall and LV posterior wall thickness were significantly reduced in STZ-treated 
mice after 6w and 12w, compared to corresponding control mice (Fig. 2a,b). Consistent with Shepherd and col-
leagues24, we detected a reduction in mean diastolic LV internal diameter in 6w, 9w, and 12w STZ mice com-
pared to control mice (Fig. 2c). This was paralleled by a decline in end-diastolic LV volume at 6w, 9w, and 12w 
post-STZ versus controls (Fig. 2d). With respect to the LV mass and LV mass/body weight ratio, 9w STZ mice 
differed from 6w and 12w STZ mice, as indicated by increased diastolic LV anterior wall and LV posterior wall 
values. Specifically, LV anterior wall thickness of 9w STZ mice was higher compared to 6w STZ and 12w STZ 
mice, respectively. Analogously, LV posterior wall thickness was increased at STZ 9w versus STZ 6w and 12w, 
respectively. As reported previously25–27, diastolic wall strain (DWS), which displays the differences of posterior 
LV wall thickness during systole and diastole, is proposed to be a marker for diastolic function and correlates with 
LV stiffness. Compared to the respective controls, 6w STZ mice displayed increased DWS, whereas DWS was 
reduced in 9w STZ mice (Fig. 2e). Similar to LV wall thicknesses, differences between 9w STZ mice versus 6w STZ 
and 12w STZ mice were detected, respectively.
In agreement with existing data3,24,28, we further observed reduced cardiac ejection fraction, and fractional 
shortening in 9w STZ versus control mice. In addition, stroke volume and cardiac output were decreased in STZ 
animals compared to the corresponding control mice (Supplemental Fig. 1). Comparison within the STZ groups 
revealed only a reduced ejection fraction in 9w STZ mice versus 12w STZ animals.
STZ-induced type 1 diabetes mellitus reduces global peak strain. Next, we examined global peak 
strain parameters as well as segmental deformation behaviour, indicated by regional peak strain values, to eval-
uate myocardial function. In comparison to the corresponding controls, GLS was reduced in mice at 6w, 9w, and 
12w STZ, respectively (Fig. 3a). Furthermore, the STZ 9w group displayed a decrease in GLS compared to the STZ 
6w mice. Additionally performed quantitative segmental strain analysis indicated decreased myocardial deforma-
tion behaviour of the anterior and posterior base at 9w after STZ treatment (Fig. 3c). In parallel, we observed an 
increase in GCS in 6w STZ and 12w STZ mice versus corresponding controls, respectively (Fig. 3b). In contrast, 
the 9w STZ animals displayed a lower GCS relative to 6w and 12w STZ mice, respectively. Segmental analysis of 
the respective short axis B-mode images showed improved contraction of the anterior free wall and posterior 
septum in STZ mice at 6w compared to controls (Fig. 3d). Analogous, myocardial contraction of the posterior 
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septum was increased in 12w STZ mice versus controls. These data indicate that STZ-induced diabetic cardiomy-
opathy is associated with an impairment in GLS, whereas GCS is partially improved. Additionally, the GLS and 
GCS rates, which reflect the change in strain over time, exhibited similar regulations in STZ versus control mice 
as the respective GLS and GCS (Supplemental Fig. 2).
STZ-induced type 1 diabetes mellitus modulates collagen I deposition and extracellular matrix 
turnover in a time-dependent manner. After we observed time-dependent changes in STE-assessed 
strain parameters following STZ treatment, we investigated possible underlying mechanisms. In comparison to 
the respective controls, we detected no differences in Col1a1 mRNA expression in STZ 9w animals (Fig. 4a). In 
contrast, collagen I protein expression was increased in 9w STZ mice versus controls, which was accompanied 
by an increase in the collagen I/collagen III protein ratio (Fig. 4b,c). Twelve w after STZ application, Col1a1 gene 
expression was reduced in mice, and this finding was associated with a reduction in collagen I protein expression 
(Fig. 4b). In parallel to the decline in collagen mRNA and protein levels, 12w STZ mice displayed a decrease in 
lysyl oxidase (Lox) and lysyl oxidase-like (LoxL)-2 mRNA levels compared to controls, respectively (Fig. 4d,e). 
Beside collagen cross-linking, collagen homeostasis is mainly regulated by MMPs and TIMPs. Therefore, we 
examined the expression of MMPs and TIMPs in the LV (Fig. 4f–h). Especially, MMP-8 and MMP-13 are respon-
sible for collagen I degradation, indicating their role in cardiac remodeling29. Compared to control animals, 
MMP-8 mRNA levels were elevated in 9w STZ mice, whereas MMP-13 mRNA levels were reduced in 6w and 
12w STZ mice, respectively (Fig. 4f,g). Similar to collagen I, mice at 9w STZ displayed an increase in MMP-8 and 
MMP-13 gene expression compared to the 6w STZ group. Furthermore, MMP-8 and MMP-13 mRNA levels were 
lower in 12w STZ mice versus 9w STZ mice. TIMP-1 expression showed a decline in mRNA levels at 9w and 12w 
post-STZ, respectively, compared to 6w STZ (Fig. 4h).
STZ-induced type 1 diabetes mellitus alters the cardiac proteome in a time-dependent manner. 
To further understand the changes in strain parameters, a hypothesis-free proteome analysis was performed 
(Fig. 5a–c). To this end, we applied principal component analysis yields to discriminate peptide signatures 
between the LV tissues at the different time points. The principal component-1 clearly distinguished the protein 
Figure 1. STZ-induced type 1 diabetes mellitus is associated with impaired morphological parameters. (a) 
Blood glucose levels (mg/dl) in control mice and 6w, 9w, and 12w after STZ application. Besides increased blood 
glucose, mice suffering from type 1 diabetes displayed lower body weight (g) over time (b). As morphological 
parameters, LV mass (mg; c) and LV mass/body weight (d) are depicted. Bar graphs represent the mean ± 
SEM. Data were analysed with One-way ANOVA or Kruskal-Wallis test (*p < 0.05; **p < 0.01, ***p < 0.001, 
***p < 0.0001 versus corresponding control; †p < 0.05, ††p < 0.01, †††p < 0.001, ††††p < 0.0001 versus the 6w 
STZ; ‡p < 0.05, ‡‡p < 0.01, ‡‡‡p < 0.001, ‡‡‡‡p < 0.0001 versus the 9w STZ; n = 12/controls and n = 14/STZ).
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signatures between STZ and control LV tissue at 6w, 9w and 12w (Fig. 5a). Furthermore, the comparison of the 
peptide signatures within the STZ group resulted in a clear distinction between STZ 6w, 9w and 12w, respectively 
(Fig. 5b). To further understand these changes in the cardiac proteome, the mesoderm was subsequently defined 
as region of interest and specific peptide values (m/z) were localized and identified (Fig. 5c). The spatial distri-
bution of m/z values indicated a higher intensity distribution of m/z 976 Da from cardiac α-actin, m/z 1396 Da 
from myosin light chain 3, and m/z 1063 Da from mitochondrial ATP synthase in 6w STZ versus 6w control 
mice, respectively (Table 1). In contrast, the intensity distribution of α-actin, myosin light chain 3, mitochondrial 
ATP synthase, and titin were declined in 9w STZ mice versus corresponding controls, respectively (Table 1). 
Interestingly, 12w post-STZ only α-actin, myosin light chain 3, and mitochondrial ATP synthase showed a higher 
intensity distribution compared to the respective controls (Table 1).
Figure 2. STZ-induced type 1 diabetes mellitus reduces diastolic function. To determine diastolic performance, 
left ventricular anterior wall (a), left ventricular posterior wall (b), LV internal diameter (c), and end-diastolic 
volume (d) were assessed using a Vevo 3100. In addition, diastolic wall strain (e) was calculated using posterior 
wall thicknesses during systole and diastole. Bar graphs represent the mean ± SEM. Data were analysed 
with One-way ANOVA or Kruskal-Wallis test (*p < 0.05; **p < 0.01, ***p < 0.001, ***p < 0.0001 versus 
corresponding control; †p < 0.05, ††p < 0.01, †††p < 0.001, ††††p < 0.0001 versus the 6w STZ; ‡p < 0.05, ‡‡p < 0.01, 
‡‡‡p < 0.001, ‡‡‡‡p < 0.0001 versus the 9w STZ; n = 12/controls and n = 14/STZ).
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Discussion
In the present study, we reported time- and (region)-dependent changes in the expression of cardiac collagen, 
MMP/TIMP, and proteins of the cardiac sarcomere during the development of STZ-induced type 1 diabetes 
mellitus-associated diabetic cardiomyopathy. These alterations are associated with and likely contribute to 
changes in myocardial deformation behaviour as indicated by altered GLS and GCS.
Patients suffering from diabetic cardiomyopathy exhibit distinct cardiac structural and functional alterations. 
STZ application is a suitable method to induce experimental type 1 diabetes mellitus-associated diabetic cardio-
myopathy characterized by enhanced cardiac inflammation and fibrosis3,30–32. There is increasing evidence that 
diastolic function is impaired already at early stages of diabetic cardiomyopathy, in the absence of prominent 
cardiac inflammation and fibrosis4.
However, the detection and mechanistic understanding of early cardiac dysfunction associated with patho-
logical remodelling, has been a major challenge for several decades of research33,34. STE-based strain analysis 
provides an attractive tool for the assessment of global cardiac function and allows the detection of subtle changes 
in tissue deformation. As such, recent guidelines for diagnosis of heart failure include the assessment of GLS9. 
However, the link between myocardial deformation and underlying changes in structural proteins in the context 
of diabetic cardiomyopathy is still little explored. Only a few studies5,24,35 have determined global LV function 
via strain parameters in the context of experimental diabetic cardiomyopathy so far. Therefore, the aim of our 
study was to evaluate myocardial deformation in combination with the underlying changes in the expression 
of structural components during the pathogenesis of STZ-induced type 1 diabetes mellitus-associated diabetic 
cardiomyopathy.
Here, we observed an impairment of GLS and GLS rate after STZ application, which is consistent with findings 
in patients suffering from heart failure with preserved ejection fraction13 and diabetes mellitus14. Additionally 
performed regional peak strain analysis implicated that these changes in GLS, which were the most prominent 
at 9w, were probably caused by less myocardial contraction of the anterior and/or posterior base. Supporting the 
recently proposed hypothesis that a loss in longitudinal deformation behaviour is compensated by improved 
circumferential deformation behaviour15, we detected an enhancement in GCS and GCS rate in 6w and 12w STZ 
Figure 3. STZ-induced type 1 diabetes mellitus reduces global peak strain. Two-dimensional STE was used 
to further determine GLS (a) and GCS (b). Quantitative segmental analysis in long axis (c) and short axis 
view (d) confirmed time-dependent changes in myocardial deformation behaviour. AA Anterior Apex; AB 
Anterior Base; AFW Anterior Free Wall; AM Anterior Mid; AS Anterior Septum; IFW Inferior Free Wall; LW 
Lateral Wall; PA Posterior Apex; PB Posterior Base; PM Posterior Mid; PS Posterior Septal Wall; PW Posterior 
Wall. Bar graphs represent the mean ± SEM. Data were analysed with One-way ANOVA or Kruskal-Wallis 
test (*p < 0.05; **p < 0.01, ***p < 0.001, ***p < 0.0001 versus corresponding control; †p < 0.05, ††p < 0.01, 
†††p < 0.001, ††††p < 0.0001 versus the 6w STZ; ‡p < 0.05, ‡‡p < 0.01, ‡‡‡p < 0.001, ‡‡‡‡p < 0.0001 versus the 9w 
STZ; n = 12/controls and n = 14/STZ).
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mice. In contrast, GCS and GCS rate of 9w STZ mice were reduced relative to 6w and 12w STZ mice, and this 
effect was paralleled by a lack of changes in segmental contraction. Interestingly, Shepherd and colleagues, who 
also used a STE-based approach, detected no change in GLS in 6w STZ mice, whereas GCS, global radial peak 
strain and subsequently strain rates were reduced24. In contrast to our study, in which we performed quantitative 
analysis on each of the 6 single segments, Shepherd and colleagues grouped the long- and short axis images only 
into 2 segments, which disables a direct comparison between the studies. However, we believe that by the group-
ing of segments, the added value of the regional analysis, which is actually the advantage of this method, goes lost. 
Therefore, we are not surprised that the authors only reported regional changes of the global radial peak strain, 
but not of the GLS. In addition to GLS and GCS, we also investigated DWS as a marker of diastolic function. 
Non-invasive assessment of LV wall stiffness in experimental models was first established by Takeda et al.25 who 
reported an inverse correlation of DWS with myocardial stiffness. Despite the lack of correlation in larger patient 
cohorts26, reduced DWS may be associated with a decreased diastolic function27, which has been confirmed by 
our findings.
As first stated by Greenbaum and colleagues in 19816, the LV consists of longitudinal and circumferen-
tial fibres, with GLS being mainly determined by contraction of longitudinal fibres8. For diabetes mellitus, it 
is hypothesized that longitudinal fibres are more affected by extracellular matrix turnover16. In our study, we 
Figure 4. STZ-induced type 1 diabetes mellitus modulates collagen I deposition and cross-linking in a time-
dependent manner. 6w, 9w, and 12w after diabetes induction, Col1a1 mRNA (a) and collagen I protein levels 
(b) were investigated. Immunohistological staining is shown by representative images (scale bar = 200 μm; 
middle panel). To further characterize cardiac fibrosis, collagen I/III protein ratio (c), Lox (d), and LoxL-2 (e) 
gene expression were measured. Additionally, mRNA levels of MMP-8, MMP-13, and TIMP-1 were detected 
(f–h). Quantification of the positive area (%)/HA (mm2) was performed via digital image analysis. Bar graphs 
represent the mean ± SEM. Data were analysed with One-way ANOVA or Kruskal-Wallis test (*p < 0.05; 
**p < 0.01, ***p < 0.001, ***p < 0.0001 versus corresponding control; †p < 0.05, ††p < 0.01, †††p < 0.001, 
††††p < 0.0001 versus the 6w STZ; ‡p < 0.05, ‡‡p < 0.01, ‡‡‡p < 0.001, ‡‡‡‡p < 0.0001 versus the 9w STZ; n = 5–6/
controls and n = 5–6/STZ).
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detected a reduction in GLS, which is mainly determined by longitudinal fibres. In parallel, collagen I deposition 
was increased at 9w STZ. Interestingly, we observed less collagen I at 12w post-STZ compared to 9w STZ, paral-
leled by lower Lox and LoxL2 levels, as markers for collagen cross-linking36. The reduction in collagen at 12w STZ 
Figure 5. STZ-induced type 1 diabetes mellitus is associated with alterations in proteins indicative for 
contractile function in a region- and time-dependent manner using IMS. (a) Principal component analysis from 
LV tissues at 6w, 9w, and 12w after diabetes induction, clearly distinguished between STZ and control mice. (b) 
Principal component analysis of STZ 6w versus 9w, and 12w showed differences of in the intensity distribution 
within the STZ group. (c) H/E staining of control (left panel; scale bar = 1 mm) and STZ (right panel) mice with 
the corresponding spatial intensity distribution of 976 Da (cardiac α-actin), 1396 Da (myosin light chain 3), 
1026 Da (mitochondrial ATP synthase subunit alpha) and 1503 Da (Titin).
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per se is contradictory to already published studies, reporting higher collagen levels3,23,31. Only one study, inves-
tigating the effect of thioredoxin-interacting protein, reported less myocardial collagen at 16w STZ compared to 
controls37. But alterations in extracellular matrix, especially collagen, are not only determined by production and 
cross-linking, but also by degradation. Extracellular matrix degradation is predominantly regulated by MMPs, 
which are counteracted by TIMPs. Several studies have previously connected the dysregulation in MMPs/TIMPs 
and subsequent collagen deposition in STZ-induced type 1 diabetes mellitus-associated diabetic cardiomyopa-
thy with an impairment of myocardial function31,38. With respect to our study, changes in cardiac MMP-8 and 
MMP-13 gene expression levels were observed after STZ application, suggesting a time-dependent modulation 
in collagen degradation.
Recently, we have demonstrated layer-specific changes in extracellular matrix proteins, which resulted in 
layer-specific changes of strain parameters in an experimental model of isolated subendocardial fibrosis20. Based 
on these findings, IMS was applied to further investigate global and regional-dependent changes in cardiac pro-
tein signature. In accordance to previous proteome analysis in experimental type 139 and type 2 diabetes40, we 
detected alterations in intensity distribution of proteins, which are associated with cardiac energy metabolism 
and contractile function and play a crucial role in the progression of diabetic cardiomyopathy41. The higher dis-
tribution of α-actin, myosin light chain 3, ATP synthase, and titin in 6w STZ mice compared to control animals, 
might be a compensatory mechanism to counteract the reduced GLS and could hypothetically be reflected in the 
increased GCS. Similar observations were made in cardiac contractility modulation patients, where improved 
cardiac function was associated with an increased expression of contractile proteins, including myosin light 
chain and titin42. In contrast to that, the intensity distribution of all mentioned protein signatures was reduced in 
9w STZ mice versus controls, which was paralleled by an increased collagen I/III ratio. These changes probably 
underlie the impaired GCS and GLS, indicative for reduced myocardial deformation behaviour. At 12w post-STZ, 
mice exhibited decreased myocardial α-actin, myosin light chain 3, and ATP synthase levels compared to con-
trols. Nevertheless, titin was unaffected in 12w STZ mice, which might be an explanation for the lack of significant 
improvement in GCS compared to the respective controls, whereas GCS at 12w post-STZ was increased relative 
to 9w post-STZ.
Future directions and limitations. Given the high sensitivity of STE-derived myocardial deformation 
data (global peak strain and global peak strain rate), this technique is recommended as a non-invasive diagnostic 
method for extensive clinical use43,44. Both data allow the early detection of myocardial dysfunction of different 
aetiologies and provide prognostic information. They are easy to acquire for a trained expert in echocardiography 
and helpful for therapeutic decision making and follow-up examinations. Despite these valuable advantages, 
clinical application of STE is still challenging45. Only standardization of measurements, continued training, and 
quality assurance ensure less measurement differences between various vendors/observers and allow an accurate 
interpretation. To date, STE-derived myocardial deformation data only in conjunction with other parameters, 
such as ejection fraction, are used for clinical decision making. The combination of STE with IMS allows time- 
and region-dependent alterations on molecular and functional outcome in the pathogenesis of STZ-induced type 
1 diabetic cardiomyopathy. Especially, since it was not expected to see this specific cardiac phenotype found at 
12w post STZ, including a decrease in collagen content, in comparison to the 9w and 6w post STZ time points. 
With respect to the existing literature, our findings are contradictory and were only confirmed by Myers et al.37. 
This discrepancy in findings might be explained by the STZ model. Even if the STZ-induced type 1 diabetes 
mellitus model is considered as the standard model for experimental type 1 diabetic cardiomyopathy, it should 
be taken into account that STZ is a chemical cytotoxic glucose analogue46. In this sense, the STZ-induced type 




6w STZ vs. 
6w Control
p-value 6w 
STZ vs. 6w 
Control
ROC [AUC] 
9w STZ vs. 
9w Control
p-value 9w 
STZ vs. 9w 
Control
ROC [AUC] 
12w STZ vs. 
12w Control
p-value 12w 
STZ vs. 12w 
Control Mr IMS LC-MS △ [Da] protein name
976.569 0.27 0.683099 <0.01 0.171841 <0.01 0.323569 <0.01 975.5617 975.4410 0.120691643
α-actin
1500.603 0.27 0.643767 <0.01 0.151043 <0.01 0.309509 <0.01 1499.5957 1499.7004 −0.104770521
1956.061 0.27 0.780955 <0.01 0.277548 <0.01 0.370325 <0.01 1955.0537 1955.0363 0.017307909
2227.932 0.27 0.807939 <0.01 0.307902 <0.01 0.314609 <0.01 2226.9247 2227.0579 −0.133232170
2244.940 0.27 0.690501 <0.01 0.248110 <0.01 0.336561 <0.01 2243.9327 2243.0528 0.879852830
1396.660 0.27 0.785575 <0.01 0.216586 <0.01 0.261510 <0.01 1395.6527 1395.7470 −0.094326783
myosin light chain 31501.683 0.27 0.752211 <0.01 0.235596 <0.01 0.352482 <0.01 1500.6757 1500.6732 0.002447283
1722.797 0.27 0.719975 <0.01 0.377262 <0.01 0.357083 <0.01 1721.7897 1721.8406 −0.050969172
1026.516 0.27 0.631519 <0.01 0.327338 <0.01 0.350877 <0.01 1025.5087 1025.5869 −0.078244313 mitochondrial ATP 
synthase1575.657 0.27 0.678074 <0.01 0.391201 <0.01 0.407280 >0.05 1574.6497 1574.7787 −0.129080421
979.539 0.27 0.580183 >0.05 0.383627 <0.01 0.468888 >0.05 978.5317 978.5385 −0.006897137
Titin
1503.572 0.27 0.520056 >0.05 0.362746 <0.01 0.447791 >0.05 1502.5647 1502.7365 −0.171821676
Table 1. ROC analysis of the intensity distribution from MALDI-IMS-derived identified proteins. 
Peptides with lowest mass difference to the LC-MS/MS reference list value and with similar discrimination 
characteristics were assumed as a match.
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human type 1 diabetes mellitus, which is an autoimmune disorder46,47. Furthermore, since no uniform protocol 
to induce type 1 diabetes mellitus in rodents exists48,49, this consequently results in different severities of experi-
mental diabetic cardiomyopathy (e.g. rats display a more severe phenotype compared to mice), which ultimately 
leads to a poor comparability of experimental type 1 diabetes mellitus models in rodents. This highlights the need 
for comprehensive cardiac phenotyping in the context of experimental diabetic cardiomyopathy and supports the 
value of our study.
conclusions
This experimental study in an early stage model of type 1 diabetes mellitus-associated diabetic cardiomyopa-
thy illustrates the strengths of two-dimensional STE to detect subtle, segmental changes in LV deformation 
important for the early diagnosis of diabetic cardiomyopathy and, in general, to assess ongoing cardiac remod-
elling processes. The combination of STE with IMS, allowing the respective assessment of region-dependent 
functionality and protein expression, is unique in its kind. We are the first to our knowledge combining both 
imaging techniques. The present study illustrates that during the development of STZ-induced type 1 diabetes 
mellitus-associated diabetic cardiomyopathy the expression of structural and contractile proteins shifts in a time- 
and region-dependent manner.
Methods
Animals. Type 1 diabetes mellitus was induced in eight-week-old male C57BL6/j mice (Charles Rivers, 
Sulzfeld, Germany) via intraperitoneal injection of STZ (50 mg/kg body weight; Sigma-Aldrich, Taufkirchen, 
Germany, n = 14) on 5 consecutive days4. In parallel, controls received the appropriate volume of 0.1 mol/L 
sodium citrate (n = 12). Blood glucose measurements using the Accu-Chek Aviva® (Roche Diabetes Care 
Deutschland GmbH, Mannheim, Germany) were performed one week before STZ application and afterwards 
once a w to confirm hyperglycemia after 4 hours (h) fasting. Mice were group housed under standard housing 
conditions (12 h light/dark cycle, 50–70% humidity, 19–21 °C) within a specific pathogen free facility with food 
and water ad libitum. Cages were enriched with houses, bedding material, and gnawing sticks. All investigations 
were performed in accordance with to the European legislation for animal welfare (Directive 2010/63/EU) and 
approved by the local ethics committee (Landesamt für Gesundheit und Soziales, Berlin, G0254/13).
Echocardiography. Six, 9, and 12w after type 1 diabetes mellitus induction, echocardiographic measure-
ments were performed using a Vevo 3100 Imaging System coupled to a 30-MHz linear-frequency transducer 
(FUJIFILM VisualSonics, Toronto, ON, Canada). According to our previously published standard operating pro-
tocol20, mice were anesthetized with isoflurane (Abbott Laboratories, Abbott Park, IL, USA) and fixed in a supine 
position. To obtain constant heart rates, isoflurane concentrations were reduced to 1–2%. Next, mice were depil-
ated using hair-removal crème, and pre-warmed ultrasound gel (Parker Laboratories, Fairfield, NJ, USA) was 
placed on the chest. B- and M-Mode images were acquired in parasternal long axis and short axis view. A trained 
expert in small animal echocardiography performed STE analysis of the B-Mode images in a semiautomatic man-
ner using the VevoStrain software package (FUJIFILM VisualSonics), as reported previously20. Determination of 
cardiac systolic function was performed in a semiautomatic manner from the respective B-mode images (long 
axis view) using the monoplane Simpson method of disks. To calculate LV dimensions and LV mass, the acquired 
M-Mode images of the parasternal long axis view were used. In detail, three independent M-Mode images and 
3 cardiac cycles were analysed. To determine diastolic function, DWS was calculated as previously described27.
Tissue preparation for molecular investigations. To examine gene and protein expression, an addi-
tional set of experiments was performed. To this end, type 1 diabetes mellitus was induced as mentioned above. 
At the respective time points (6w, 9w, and 12w after STZ application or control treatment), 5–6 mice/group were 
euthanized via cervical dislocation and the LV was excised, immediately snap frozen in liquid nitrogen and stored 
at −80 °C until further processing. To confirm characteristics of the echocardiographic set, blood glucose levels, 
body weight, LV weight and LV weight/body weight ratio derived from the second set of animals were depicted 
(Supplemental Fig. 3).
RNA isolation and gene expression analyses from heart tissue. LV RNA was isolated using the 
TRIzol® method, as described in detail elsewhere50. According to manufacturer’s protocol, the RNA pellet 
was purified with the RNeasy Mini Kit (Qiagen, Hilden, Germany) and subsequently transcribed into cDNA 
using the High Capacity Kit (life Technologies, Darmstadt, Germany). Real-time PCR was performed using 
the following gene expression assays (all provided by Applied Biosystems, Darmstadt, Germany): Col1a1 
(Mm01302043_g1), Lox (Mm00495386_m1), LoxL-2 (Mm00804740_m1), MMP-8 (Mm00439509_m1), MMP-
13 (Mm00439491_m1), and TIMP-1 (Mm00441818_m1). Gene expression levels were normalized towards 
CDKN1b (Mm00438167_g1) and expressed as the n-fold change to the respective control group, set as 1.
Immunohistology. Frozen LV were embedded in Tissue-Tek (Sakura, Staufen, Germany) for cryosectioning 
and subsequent staining. As described previously51, specific antibodies directed against Collagen I (Chemicon, 
Limburg/Lahn, Germany) and Collagen III (Merck Millipore, Darmstadt, Germany) were used. Quantitative 
analysis of the positive area (%)/heart area (HA; mm2) was performed by digital image analysis on a Leica 
DM2000 light microscope (Leica Microsystems, Wetzlar, Germany) at 100× magnification.
Left ventricular proteome analysis by MALDI-Imaging mass spectrometry. MALDI-IMS was 
performed as previously described52. In brief, formalin-fixed paraffin embedded (FFPE) LV sections of 6 µm were 
transferred onto Indium-Tin-Oxide slides (Bruker Daltonik, Bremen, Germany), dewaxed and passed through 
decreasing concentrations of ethanol53. Next, trypsin solution was applied onto the sections via an automated 
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spraying device (ImagePrep; Bruker Daltonik) for 3 h incubation (37 °C; moist chamber). Finally, matrix solution 
(α-cyano-4-hydroxycinnamic acid) was applied using ImagePrep. For MALDI-IMS data acquisition, the positive 
ion reflector mode on an MALDI-TOF/MS (Autoflex III; Bruker Daltonik) was used. The corresponding detection 
range and raster width were set as 800–3500 Da and 100 µm, respectively. After MALDI-IMS experiments, tissue 
sections were stained with haematoxylin and eosin (H/E) to define the region of interest. As previously reported53, 
m/z values were identified via complementary protein identification using the “bottom-up”-nano liquid chroma-
tography (Dionex Ultimate 3000, Thermo fischer) - MS/MS (ESI-QTOF; Bruker Daltonik) approach. Mass spectra 
were analysed using the mascot search engine (version 2.4, MatrixScience, UK) searching the UniProt database. 
To this end, the following parameters were set: (i) taxonomy: mus musculus (ii) proteolytic enzyme: trypsin, (iii) 
peptide tolerance: 10 ppm, (iv) maximum of accepted missed cleavages: 1, (v) peptide charge: 2+, 3+, 4+; (vi) 
variable modification: oxidation (M); (vii) MS/MS tolerance: 0.05 Da, and (viii) MOWSE score > 25. Identification 
of MALDI-IMS m/z values by using an LC-MS/MS reference list requires the accordance of more than one peptide 
(mass differences <0.9 Da) to subsequently correctly assign the corresponding protein54.
Statistical analysis. All Data are expressed as mean ± SEM and statistical analysis was performed using the 
GraphPad Prism 8 Software (GraphPad Software, La Jolla, CA, USA). Differences between the groups were assessed 
using the One-way ANOVA (Fisher´s LSD post hoc test) or Kruskal-Wallis Test (Dunn´s post hoc test) and consid-
ered significant at a value of p < 0.05. For IMS-proteome data, statistical analysis was performed using the SCiLS Lab 
software (Version 2015b, SCiLS GmbH, Bremen, Germany), as described before52. To define common molecular fea-
tures among the sample sets, unsupervised multivariate principal component analysis for mass spectra was applied 
for each time point separately. The mesoderm was defined at the corresponding H/E staining as region of interest 
from STZ as well as controls. Additionally, principal component analysis was performed in the STZ group at the 
different time points. A receiver operating characteristic (ROC) analysis was performed pairwise (STZ vs control) 
to identify discriminating properties (peptides) in the mesoderm of LV tissue specimens at 6w, 9w, and 12w after 
type 1 diabetes mellitus induction. For those peaks with a ROC score of AUC > 0.6 or <0.4, a univariate hypothesis 
test (Wilcoxon rank sum test) was used to ensure the statistical significance of m/z values. Results with significant 
differences (p-value ≤ 0.01) in the Wilcoxon test were assumed to be potential markers.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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